Suvi‐Katri Leivonen
Impact in
- Cancer Research top 1%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Molecular Biology top 5%
- Circular RNAs in diseases
- RNA modifications and cancer
- TGF-β signaling in diseases
- RNA Research and Splicing
Papers in
- Oncology 22
- Cancer Immunotherapy and Biomarkers 11
-
- MicroRNA in disease regulation 15
- Cancer-related molecular mechanisms research 7
- Co-authors
- Veli‐Matti Kähäri (8 shared papers)Olli Kallioniemi (15 shared papers)Merja Perälä (14 shared papers)Sirpa Leppä (27 shared papers)Rami Mäkelä (9 shared papers)Kristine Kleivi Sahlberg (12 shared papers)Anne‐Lise Børresen‐Dale (5 shared papers)Lari Häkkinen (2 shared papers)
In The Last Decade
Suvi‐Katri Leivonen
52 papers receiving 2.4k citations
Peers
Comparison fields: 5 of 99
- Cancer Research 1.0k
- Molecular Biology 1.3k
- Oncology 443
- Pathology and Forensic Medicine 270
- Immunology 274
Countries citing papers authored by Suvi‐Katri Leivonen
This map shows the geographic impact of Suvi‐Katri Leivonen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suvi‐Katri Leivonen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suvi‐Katri Leivonen more than expected).
Fields of papers citing papers by Suvi‐Katri Leivonen
This network shows the impact of papers produced by Suvi‐Katri Leivonen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suvi‐Katri Leivonen. The network helps show where Suvi‐Katri Leivonen may publish in the future.
Co-authors
The 25 scholars most cited alongside Suvi‐Katri Leivonen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 247 | |
| 2 | 2011 | 227 | |
| 3 | 2007 | 160 | |
| 4 | 2013 | 147 | |
| 5 | 2007 | 146 | |
| 6 | 2013 | 106 | |
| 7 | 2005 | 106 | |
| 8 | 2020 | 98 | |
| 9 | 2002 | 96 | |
| 10 | 2011 | 83 | |
| 11 | 2006 | 72 | |
| 12 | 2013 | 72 | |
| 13 | 2012 | 72 | |
| 14 | 2013 | 70 | |
| 15 | 2011 | 67 | |
| 16 | 2018 | 65 | |
| 17 | 2008 | 54 | |
| 18 | 2009 | 51 | |
| 19 | 2015 | 50 | |
| 20 | 2015 | 50 |
About Suvi‐Katri Leivonen
Suvi‐Katri Leivonen is a scholar working on Oncology, Cancer Research, Molecular Biology, Pathology and Forensic Medicine and Immunology, having authored 55 papers that have together received 2.4k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (16 papers), MicroRNA in disease regulation (15 papers), Cancer Immunotherapy and Biomarkers (11 papers), Immune Cell Function and Interaction (7 papers), TGF-β signaling in diseases (7 papers), Cancer-related molecular mechanisms research (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Circular RNAs in diseases (4 papers). The work is most often cited by research in Cancer Research (1.0k citations), Molecular Biology (1.3k citations), Oncology (443 citations), Pathology and Forensic Medicine (270 citations) and Immunology (274 citations). Suvi‐Katri Leivonen has collaborated with scholars based in Finland, Norway and Sweden. Frequent co-authors include Veli‐Matti Kähäri, Olli Kallioniemi, Merja Perälä, Sirpa Leppä, Rami Mäkelä, Kristine Kleivi Sahlberg, Anne‐Lise Børresen‐Dale, Lari Häkkinen, Teijo Pellinen and Marja‐Liisa Karjalainen‐Lindsberg. Their work appears in journals such as PLoS ONE, Haematologica, Blood, Cancers and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.